Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
Information provided by:
Istituto Clinico Humanitas
ClinicalTrials.gov Identifier:
NCT00763607
First received: September 30, 2008
Last updated: September 1, 2010
Last verified: September 2010
  Purpose

Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients

The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.


Condition Intervention
Non Small Cell Lung Cancer
Genetic: Protein expression by immunohistochemistry and immunofluorescence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Istituto Clinico Humanitas:

Primary Outcome Measures:
  • Association of different biomarkers with survival [ Time Frame: At the end of enrollment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Association of a specific biomarker with patient's characteristics [ Time Frame: At the end of enrollment ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Paraffine embedded tumor sections


Estimated Enrollment: 454
Study Start Date: November 2007
Study Completion Date: December 2009
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Radically resected Non small cell lung cancer patients in stage I-III
Genetic: Protein expression by immunohistochemistry and immunofluorescence
Protein expression by immunohistochemistry and immunofluorescence

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Radically resected non small cell lung cancer patients

Criteria

Inclusion Criteria:

  • Radically resected non small cell lung cancer patients with tumor tissue available

Exclusion Criteria:

  • Tumor tissue not available
  • Clinical data not available
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00763607

Locations
Italy
Istituto Clinco Humanitas
Rozzano, Milan, Italy, 20089
Sponsors and Collaborators
Istituto Clinico Humanitas
Investigators
Principal Investigator: Armando Santoro, MD Istituto Clinico Humanitas
  More Information

No publications provided

Responsible Party: Armando Santoro, MD, Istituto Clinico Humanitas
ClinicalTrials.gov Identifier: NCT00763607     History of Changes
Other Study ID Numbers: ONC/OSS-02/2007
Study First Received: September 30, 2008
Last Updated: September 1, 2010
Health Authority: Italy: Ministry of Health

Keywords provided by Istituto Clinico Humanitas:
non small cell lung cancer patients

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on November 27, 2014